Cue Biopharma, Inc. Increase (Decrease) in Accrued Liabilities
Cue Biopharma, Inc. (CUE) reported Increase (Decrease) in Accrued Liabilities of $15.72 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-14
- Cue Biopharma, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $15.84M.
- Cue Biopharma, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$112.00K, a 108.47% decline year-over-year.
- Cue Biopharma, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was -$259.00K.
- Cue Biopharma, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $352.00K.
- Cue Biopharma, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was -$1.30M.
- Cue Biopharma, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was -$1.23M, a 309.01% decline from fiscal 2023.
- Cue Biopharma, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was $588.00K.
- Cue Biopharma, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was -$1.07M, a 158.44% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month | Increase (Decrease) in Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $15.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $15.72M 10-Q · filed 2026-08-14 | $15.46M derived: sum of 3 quarters · filed 2026-08-14 | $15.82M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | -$112.00K 10-Q · filed 2026-05-14 | -$371.00K derived: sum of 2 quarters · filed 2026-05-14 | -$19.00K derived: sum of 3 quarters · filed 2026-05-14 | -$2.73M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | -$259.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $93.00K derived: sum of 2 quarters · filed 2026-03-16 | -$2.62M derived: sum of 3 quarters · filed 2026-08-14 | -$1.30M 10-K · filed 2026-03-16 | |
| 2025-09-30 | $352.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$2.36M derived: sum of 2 quarters · filed 2026-08-14 | -$1.04M 10-Q · filed 2025-11-12 | -$1.33M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | -$2.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$1.39M 10-Q · filed 2026-08-14 | -$1.68M derived: sum of 3 quarters · filed 2026-08-14 | -$3.04M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | $1.32M 10-Q · filed 2026-05-14 | $1.03M derived: sum of 2 quarters · filed 2026-05-14 | -$333.00K derived: sum of 3 quarters · filed 2026-05-14 | -$978.00K derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | -$291.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$1.66M derived: sum of 2 quarters · filed 2026-03-16 | -$2.30M derived: sum of 3 quarters · filed 2026-03-16 | -$1.23M 10-K · filed 2026-03-16 | |
| 2024-09-30 | -$1.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$2.01M derived: sum of 2 quarters · filed 2025-11-12 | -$938.00K 10-Q · filed 2025-11-12 | -$1.92M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | -$645.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $426.00K 10-Q · filed 2025-08-12 | -$559.00K derived: sum of 3 quarters · filed 2025-08-12 | $493.00K derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $1.07M 10-Q · filed 2025-05-12 | $86.00K derived: sum of 2 quarters · filed 2025-05-12 | $1.14M derived: sum of 3 quarters · filed 2025-05-12 | $2.37M derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | -$985.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $67.00K derived: sum of 2 quarters · filed 2025-03-31 | $1.30M derived: sum of 3 quarters · filed 2025-03-31 | $588.00K 10-K · filed 2025-03-31 | |
| 2023-09-30 | $1.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $2.28M derived: sum of 2 quarters · filed 2024-11-14 | $1.57M 10-Q · filed 2024-11-14 | $1.24M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $1.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $521.00K 10-Q · filed 2024-08-14 | $191.00K derived: sum of 3 quarters · filed 2024-08-14 | $512.00K derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | -$709.00K 10-Q · filed 2024-05-09 | -$1.04M derived: sum of 2 quarters · filed 2024-05-09 | -$718.00K derived: sum of 3 quarters · filed 2024-05-09 | -$565.00K derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | -$330.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$9.00K derived: sum of 2 quarters · filed 2024-03-28 | $144.00K derived: sum of 3 quarters · filed 2024-03-28 | -$1.07M 10-K · filed 2024-03-28 | -$1.07M 10-K · filed 2023-03-21 |
| 2022-09-30 | $321.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $474.00K derived: sum of 2 quarters · filed 2023-11-03 | -$741.00K 10-Q · filed 2023-11-03 | -$110.25K derived: sum of 4 quarters · filed 2023-11-03 | |
| 2022-06-30 | $153.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$1.06M 10-Q · filed 2023-08-08 | -$431.25K derived: sum of 3 quarters · filed 2023-08-08 | $1.55M derived: sum of 4 quarters · filed 2023-08-08 | |
| 2022-03-31 | -$1.22M 10-Q · filed 2023-05-09 | -$584.25K derived: sum of 2 quarters · filed 2023-05-09 | $1.40M derived: sum of 3 quarters · filed 2023-05-09 | $1.43M derived: sum of 4 quarters · filed 2023-05-09 | |
| 2021-12-31 | $630.75K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | $2.62M derived: sum of 2 quarters · filed 2023-03-21 | $2.64M derived: sum of 3 quarters · filed 2023-03-21 | $1.83M 10-K · filed 2023-03-21 | |
| 2021-09-30 | $1.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $2.01M derived: sum of 2 quarters · filed 2022-11-14 | $1.20M 10-Q · filed 2022-11-14 | $1.41M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | $27.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$784.00K 10-Q · filed 2022-08-04 | -$579.14K derived: sum of 3 quarters · filed 2022-08-04 | -$2.06M derived: sum of 4 quarters · filed 2022-08-04 | |
| 2021-03-31 | -$811.00K 10-Q · filed 2022-05-10 | -$606.14K derived: sum of 2 quarters · filed 2022-05-10 | -$2.08M derived: sum of 3 quarters · filed 2022-05-10 | $831.86K derived: sum of 4 quarters · filed 2022-05-10 | |
| 2020-12-31 | $204.86K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | -$1.27M derived: sum of 2 quarters · filed 2022-03-16 | $1.64M derived: sum of 3 quarters · filed 2022-03-16 | $559.86K 10-K · filed 2022-03-16 | |
| 2020-09-30 | -$1.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $1.44M derived: sum of 2 quarters · filed 2021-11-09 | $355.00K 10-Q · filed 2021-11-09 | $1.03M derived: sum of 4 quarters · filed 2021-11-09 | |
| 2020-06-30 | $2.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $1.83M 10-Q · filed 2021-08-09 | $2.51M derived: sum of 3 quarters · filed 2021-08-09 | $1.48M derived: sum of 4 quarters · filed 2021-08-09 | |
| 2020-03-31 | -$1.08M 10-Q · filed 2021-05-10 | -$410.71K derived: sum of 2 quarters · filed 2021-05-10 | -$1.44M derived: sum of 3 quarters · filed 2021-05-10 | -$1.00M derived: sum of 4 quarters · filed 2021-05-10 | |
| 2019-12-31 | $672.29K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | -$352.71K derived: sum of 2 quarters · filed 2021-03-09 | $78.29K derived: sum of 3 quarters · filed 2021-03-09 | $439.29K 10-K · filed 2021-03-09 | |
| 2019-09-30 | -$1.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$594.00K derived: sum of 2 quarters · filed 2020-11-09 | -$233.00K 10-Q · filed 2020-11-09 | -$713.02K derived: sum of 4 quarters · filed 2020-11-09 | |
| 2019-06-30 | $431.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $792.00K 10-Q · filed 2020-08-07 | $311.98K derived: sum of 3 quarters · filed 2020-08-07 | $1.46M derived: sum of 4 quarters · filed 2020-08-07 | |
| 2019-03-31 | $361.00K 10-Q · filed 2020-05-07 | -$119.03K derived: sum of 2 quarters · filed 2020-05-07 | $1.02M derived: sum of 3 quarters · filed 2020-05-07 | $1.60M derived: sum of 4 quarters · filed 2020-05-07 | |
| 2018-12-31 | -$480.02K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $663.98K derived: sum of 2 quarters · filed 2020-03-12 | $1.24M derived: sum of 3 quarters · filed 2020-03-12 | $636.98K 10-K · filed 2020-03-12 | |
| 2018-09-30 | $1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $1.72M derived: sum of 2 quarters · filed 2019-11-07 | $1.12M 10-Q · filed 2019-11-07 | $1.51M derived: sum of 4 quarters · filed 2019-11-07 | |
| 2018-06-30 | $572.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$27.00K 10-Q · filed 2019-08-08 | $368.31K derived: sum of 3 quarters · filed 2019-08-08 | $530.31K derived: sum of 4 quarters · filed 2019-08-08 | |
| 2018-03-31 | -$599.00K 10-Q · filed 2019-05-08 | -$203.69K derived: sum of 2 quarters · filed 2019-05-08 | -$41.69K derived: sum of 3 quarters · filed 2019-05-08 | ||
| 2017-12-31 | $395.31K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $557.31K derived: sum of 2 quarters · filed 2019-03-14 | $712.31K 10-K · filed 2019-03-14 | ||
| 2017-09-30 | $162.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $317.00K 10-Q · filed 2018-11-13 | |||
| 2017-06-30 | $155.00K 10-Q · filed 2018-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |